INTRODUCTION
Cancers are rare among patients aged 15 to 39 years. Nevertheless, there were >60,000 cancers diagnosed in this age group in 2002, which is more than was diagnosed in the pediatric age group. Cancer also was the most common cause of diseaserelated death in this age group. Of the various cancers encountered, leukemia represents a small fraction of the total cancers diagnosed, with an incidence of 2.7 cases per 100,000 population. However, the incidence of leukemia varies considerably throughout the AYA age spectrum, being more prominent in patients closer to age 15 years than to age 39 years. At the time of presentation, symptoms tend to be vague, constitutional complaints. The diagnostic evaluation generally is straightforward, with a complete blood count and bone marrow evaluation performed once the diagnosis has been considered. As in pediatric patients, a purely diagnostic lumbar puncture is not recommended. The majority of patients have precursor B (pre-B) acute lymphoblastic leukemia (ALL), but the T-cell percentage is higher in the AYA group compared with the pediatric group. In various studies, the average presenting white blood cell count (WBC) is within the range of 5000 to 15,000/lL. Extramedullary leukemia, mainly manifested in the spinal fluid, occurs in approximately 10% of patients. The vast majority of patients achieve a remission, as is noted among younger patients, but the current 5-year event-free survival (EFS) rate, which generally is approximately 50% to 60%, has not been as high as has been observed in younger patients.
ALL in the AYA Population: Young Adults Are Not Big Children
Pediatricians are fond of saying, "children are not little adults." The reverse is true for AYA patients with ALL. These patients are not big children. Striking differences exist between ALL occurring in the AYA population and that in the pediatric age group with regard to the genetic and molecular features of the disease. A summary of the major differences can be found in Roberts et al, as a well as a list of previous studies shown in Table 1 . [1] [2] [3] [4] [5] [6] A major disparity between the 2 populations is in the percentage of patients having what pediatricians regard as very favorable cytogenetic features. In pediatric patients with ALL who are aged <10 years, approximately 60% of newly diagnosed patients have hyperdiploidy in leukemic blasts; favorable trisomies of chromosomes 4, 10, and 17; or the TEL/AML translocation. The AYA population appears to have very few patients with these highly favorable features. At The University of Texas MD Anderson Cancer Center (MDACC) in Houston, the presence of trisomies of chromosomes 4, 10, or 17 in the AYA population is rare. In general, high-risk features are much more common in the AYA population than in the pediatric population. The percentages of patients with T-cell phenotype and with the BCR-ABL-like molecular signature are higher in the AYA population than in patients aged <15 years of age. Both these groups have a relatively poor prognosis compared with patients with standard pre-B ALL. AYA patients are more likely to present with an MLL translocation, which carries a poor prognosis and is an indication for allogeneic stem cell transplantation. Hypodiploid blasts with 44 chromosomes are a poor prognostic factor for pediatric patients. In the AYA group, this hypodiploid blast fraction is small, as it is in children. The percentage of patients with a WBC of >50,000/lL at the time of presentation, a high-risk feature in children and adults, appears to be similar in the 2 groups. The incidence of a high WBC is approximately 25% in teenage patients and in young adults. 7 The percentage of patients with extramedullary ALL, mainly central nervous system (CNS) contamination, may be slightly higher in the AYA population. In pediatric patients, CNS involvement at the time of diagnosis usually is reported in approximately 3% of cases. Young adults at MDACC present with CNS involvement approximately 10% of the time, a percentage similar that found in some pediatric studies. 8, 9 For patients with T-cell ALL, the incidence of the early precursor T-cell phenotype, a poorly responding type, is 17%. 10 Adult data regarding early precursor T-cell ALL indicates a poor prognosis for this subset of patients when compared with patients with other T-cell ALL, possibly in the presence of concomitant HOXA11 mutations.
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Delays in therapy occur in both pediatric and AYA patient groups. In the AYA population, incorrect or inappropriate treatment assignments have been reported, and may be greater than in pediatric patients with ALL. 12 Response to therapy, particularly clearance of minimal residual disease (MRD) to <0.01% by the end of induction, is a powerful prognostic indicator in pediatric patients. 13, 14 Adult studies also corroborate the prognostic importance of MRD clearance early in therapy. [15] [16] [17] Compared with children, adults with B-cell ALL are slower to achieve MRDnegative status. 18 As discussed above, the AYA population has features of the most difficult-to-treat pediatric patients and lacks many favorable prognostic factors found in young patients with ALL. The clinician treating AYA patients with ALL should be aware of the prominent subsets within the AYA population and evaluate patients for these poor prognostic features. Molecular testing for the BCR-ABL-like phenotype, flow cytometric evaluation for early precursor T-cell ALL in patients with T-cell ALL, and MRD evaluation at the end of induction improve prognostic stratification and may be used to plan further interventions such as stem cell transplantation. At the same time, the physician must be aware of the favorable features noted above to avoid the overtreatment of patients.
Choosing Therapy
Multiple national groups have performed retrospective analyses of treatment results comparing pediatric with adult chemotherapy trial results in teenagers and AYA patients ( Table 1 ). The French, Dutch, UK, and US comparisons all demonstrated significantly higher survival rates if teenagers aged 21 years were enrolled on pediatric versus adult trials. 2, 3, 5, 19 An exception occurred in Finland, where the adult trial adhered more closely to the pediatric treatment regimen, and no significant differences between adult and pediatric therapy were detected. 6 Results from completed pediatric trials in patients with high-risk ALL have demonstrated impressive improvements in outcomes for teenagers. The Children's Cancer Group explored increased intensity therapy using a chemotherapy backbone from the Berlin-FrankfurtMunster (BFM) consortium. An analysis of patients aged 15 to 21 years demonstrated 5-year event-free survival (EFS) and overall survival (OS) rates of 71.5% and 77.5%, respectively. 7 The Dana-Farber Cancer Institute consortium published their own results in subsets of teenaged patients treated on 2 consecutive trials. These trials used an intensive consolidation phase with 30 weeks of asparaginase. The 5-year EFS and OS rates for patients aged 15 to 18 years on the Dana-Farber Cancer Institute consortium trials were 77.5% and 81%, respectively, which was as good as the results reported in the younger, and supposedly lower risk, group of patients aged 10 to 15 years. 9 St. Jude's Children's Research Hospital achieved what to our knowledge are the highest 5-year EFS and OS rates at 86.4% and 87.9%, respectively, for patients aged 15 to 18 years. 4 The excellent outcomes generated by the pediatric groups, coupled with the historically worse outcomes noted with adult trials, generated enthusiasm for the use of pediatric-based chemotherapy regimens among young adults. Some groups expanded the age limit for adults on such pediatric-based therapy to age 55 years. 20 With very few exceptions, pediatric-based therapy applied to the AYA population has generated positive results (Table 2) . To the best of our knowledge, the Spanish Programa Espanol de Tratamiento en Hematologia (PETHEMA) group was among the first to publish AYA results using pediatricbased therapy; they demonstrated 6-year EFS and OS rates of 63% for young adults aged 19 to 30 years. 21 These outcomes were statistically similar to the outcomes noted in adolescents on the same protocol, and the authors concluded that pediatric therapy was advantageous in patients with ALL up to age 30 years. Huguet et al conducted a similar trial in France for patients with pre-B and T-ALL and achieved 42-month EFS and OS rates of 55% and 60%, respectively, in patients aged 15 to 45 years. 22 These results were superior to those with prior adult ALL therapy programs. A recent update of their program suggested that the benefit extended to adults up to age 55 years. 22 In the United States, single-institution studies explored the feasibility of administering pediatric chemotherapy regimens to older adults. Douer et al demonstrated that pediatrictype therapy was tolerable and effective for induction in adults up to age 55 years. 23 At MDACC, augmented BFM therapy, the therapy used in the above Children's Cancer Group trial, was given to adults up to age 40 years and the 5-year EFS and OS rates were 53% and 60%, respectively. 24 A large intergroup trial in AYA patients with ALL also has shown that augmented BFM therapy can be administered with acceptable toxicity in the cooperative group setting. The 2-year EFS and OS rates on this intergroup trial were 66% and 78%, respectively. 25 The above trials applied pediatric-based therapy to young and to some older adults with good effect. However, not all adult trials have had inferior outcomes compared with pediatric therapy in AYA patients with ALL. As mentioned, the Finnish analysis demonstrated similar outcomes between their adult and pediatric trials in the AYA age group. 6 At MDACC, the adult regimen of rituximab plus fractionated cyclophosphamide, doxorubicin, vincristine, and dexamethasone alternating with methotrexate and high-dose cytarabine (R-hyper-CVAD) produced a 3-year complete remission duration of 60% and an OS rate of 50% in adults aged <60 years. Younger adults fared even better on this study. A subset analysis of patients aged <40 years who were treated either with augmented BFM therapy or R-hyper-CVAD did not demonstrate any difference in outcome between the 2 regimens. 24 The R-hyper-CVAD group produced a 3-year complete remission duration and OS rate of 66% and 71%, respectively, which were virtually identical to the results noted with augmented BFM. 24 In the late 1980s, Larson et al obtained similar results using a regimen that remarkably recapitulated pediatric-type therapy. 26 Adult protocols that retain the premises of pediatric therapy, including intensification phases, CNS prophylaxis, and prolonged maintenance, produce similar results compared with purely pediatricbased therapy.
Intensifying Therapy
As prognostic features, such as persistent MRD, are identified, the question arises of how to improve outcomes when poor-risk patients are identified. Pediatric trials are adapting therapy in an attempt to improve outcomes in high-risk children. In particular, MRD status guides decisions regarding treatment escalation. 27 Adding conventional cytotoxic agents to already intensive chemotherapy regimens may not be feasible. This has been attempted unsuccessfully by intensifying the hyper-CVAD regimen. 28 Nelarabine, a more specific cytotoxic chemotherapy for patients with T-cell ALL, currently is being tested in randomized studies. Allogeneic stem cell transplantation drastically augments therapy. This approach may be appropriate in the presence of adverse genetic findings such as MLL rearrangements or severe hypodiploidy. Transplantation in the event of slow MRD clearance also has been advocated by some leukemia groups. 29 However, results with chemotherapy alone have improved enough that transplantation may not be necessary for all young adults. 7 Adding targeted new agents, such as monoclonal antibodies, at the initiation of therapy or to augment conventional therapy in high-risk patients is another approach. For example, rituximab improves outcomes in patients with Burkitt leukemia and young patients with pre-B ALL when added to the hyper-CVAD regimen or intensive chemotherapy. [30] [31] [32] [33] The results from adding ofatumumab to conventional chemotherapy are pending. Trials that add nelarabine for AYA patients with T-cell ALL currently are ongoing at MDACC. Blinatumomab has been demonstrated to have activity within the setting of refractory or poorly responding B-cell ALL. 29, 34 This agent is now moving toward the frontline setting. Inotuzumab, a monoclonal antibody to CD22 with activity in patients with recurrent ALL, currently is being tested in combination with conventional chemotherapy in older, newly diagnosed patients and within the setting of disease recurrence as well. 35 Investigators still are in the process of determining at what point in therapy such agents should be used. Given the importance of early MRD negativity, the early use of targeted therapies in patients with ALL in first complete remission with or without MRD positivity appears logical.
Toxicities
As would be expected, patients encounter different toxicities depending on the ALL treatment regimen used. Pediatric therapy begins with 28 consecutive days of high-dose corticosteroids. Asparaginase also figures prominently into pediatric-based regimens. AYA patients experience weight gain, hyperglycemia, and fat infiltration of the liver during treatment with high-dose steroids. Approximately one-third of the pediatric population is overweight or obese, and similar numbers have been reported in young adults. These patients are at risk of liver dysfunction. Hyperbilirubinemia, possibly due to fatty liver infiltration as well as to the combination of vincristine plus azoles, leads to dose reductions and the omission of scheduled chemotherapy. Avascular necrosis of bone, a devastating complication at this young age, occurs to a lesser degree than what is observed among younger teenagers being treated with pediatric regimens. 20, 25 Other toxicities attributable to asparaginase, such as blood clots and pancreatitis, occur at approximately the same incidence as noted in younger patients. 25 It is interesting to note that allergic reactions to asparaginase are not reported to the same extent as in some pediatric trials. The development of silent antibodies that inactivate asparaginase is known to occur in AYA patients, but to the best of our knowledge the incidence is unclear. 36 Adult regimens (eg, hyper-CVAD) are intensive and result in a high incidence of fever and neutropenia. Transfusions also are frequent with hyper-CVAD therapy, perhaps more than what is encountered with pediatric therapy. Although hyper-CVAD uses high doses of corticosteroids, the exposure is measured in days rather than weeks and thus the resultant steroid toxicities are less. Offsetting this advantage, the number of scheduled hospital admission days is higher with the use of hyper-CVAD.
Fertility is a major concern for AYA patients because they usually are on the verge of starting families. All AYA patients should be counseled regarding fertility, and fertility preservation should be offered if it is medically possible. For males and females with ALL, cyclophosphamide and anthracyclines are of concern.
37 Fortunately, exposure to these agents on current regimens is not extreme. Male and female fertility after treatment is regularly preserved. 38 Sperm banking and oocyte preservation still should be offered, but many times are not needed for successful conception. For females, ovarian damage and early menopause after chemotherapy remain a concern.
39 Prolonged delays in childbearing may lead to difficulties with conception due to premature menopause, especially if oocyte preservation has not been performed.
Disease Recurrence
Survival for adult patients with ALL who develop disease recurrence is dismal, as is survival for early disease recurrence in pediatric patients. Approximately 40% of AYA patients with ALL will develop disease recurrence. This situation represents an unmet medical need. At comprehensive cancer centers or in hospitals with designated leukemia services, these patients may be enrolled on protocols testing new agents or combinations of agents. However, patients frequently are treated off protocol, and new information is not gained. The AYA population might benefit from a multicenter protocol specifically designed for patients with recurrent disease, as has been performed by pediatric oncology groups.
Other Considerations
AYA patients have other characteristics that complicate therapy. Historically, this group of patients tends to be treated outside of major medical centers, and the enrollment of this patient group on clinical trials is lower than for either pediatric patients or older adults. 40 This lack of representation on clinical trials has been correlated to a relatively decreased improvement in cure rates in AYA patients when compared with younger or older patients with cancer. The AYA group also tends to be underinsured, with up to 40% of individuals aged 19 to 29 years not covered by insurance. As many as 60% of young adults are not treated for their current health problems. 41, 42 Lack of insurance may at least partially determine whether patients are treated at comprehensive cancer centers versus community or public hospitals that may not offer trials for these patients. Several million young people currently have insurance coverage due to the Patient Protection and Affordable Care Act. 43 This may well change. Disappointingly, a sizeable percentage of AYA patients are not treated with what is regarded as adequate initial therapy for ALL. 12 These factors may be ameliorated when treatment is delivered in centers with higher volumes of patients with leukemia.
Noncompliance in the AYA population is a major problem. 44 These patients tend to view themselves as indestructible. They also are developing independence from their parents. Strict compliance contributes to cure rates in pediatric patients with ALL. Children who receive 90% of their oral chemotherapy doses have better outcomes. 45 Comprehensive care teams are essential in tackling these ancillary but important problems.
Conclusions
Improvements in the outcome of AYA patients have been made in the pediatric and adult setting. Therapy choice, although important, may not be as significant in determining outcomes as receiving treatment in leukemiafocused centers with care teams that specialize in the treatment of these patients. Clinical trials regularly are opening for this age group as interest has grown in treating AYA patients. Participation in such trials is encouraged. Joint efforts between pediatric and adult leukemia groups have been key to improving current outcomes for young adults with ALL, and hopefully will continue to benefit them.
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